Skip to content

CD0104 VEST II Post Marketing Surveillance Study

A Post-market Prospective Study of the VGS VEST (Venous External Support), Supporting Saphenous Vein Grafts for Coronary Bypass Graft Surgery in Patients With Severe Coronary Heart Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02332330
Acronym
VEST II
Enrollment
30
Registered
2015-01-06
Start date
2015-01-31
Completion date
2016-04-30
Last updated
2016-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Surgery

Brief summary

This study is designed to collect post market data on use of the VEST, particularly on saphenous vein grafts to the right territory of the heart.

Detailed description

The primary objective is to test the early-mid term patency rate of VEST supported Right Coronary Artery (RCA) bypass grafts. The research participants will undergo CABG preparations and CABG procedure routinely as is the standard of care. During the procedure the VEST will be implanted on the vein graft to the Right Coronary Artery according to the IFU. Perioperative care is according to standard of care. Upon discharge patient will be prescribed statins and aspirin for 6 months. Patient will attend a routine clinic visit 4-6 weeks post operatively. The last study visit will occur 3-6 months post operatively. Patients will undergo a noninvasive coronary CT angiography.

Interventions

DEVICEVEST

Sponsors

Vascular Graft Solutions Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patient scheduled for on-pump CABG on clinical grounds 2. At least one vein graft bypass indicated for right coronary artery and LIMA indicated for the LAD on clinical grounds 3. Appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and adequate vascular bed, as assessed from the pre-operative cardiac angiography.

Exclusion criteria

1. Concomitant non-CABG cardiac procedure 2. Prior cardiac surgery 3. Emergency CABG surgery (cardiogenic shock, inotropic pressure support, IABP) 4. Contraindication for on-pump CABG with cardioplegic arrest (e.g. severely calcified aorta) 5. Calcification at the intended anastomotic sites, as assessed upon opening of the chest and before VEST implantation. 6. Prior debilitating stroke less than 1 year before surgery 7. Severe renal dysfunction (Cr\>2.0 mg/dL) 8. Concomitant life-threatening disease likely to limit life expectancy to less than 2 years.

Design outcomes

Primary

MeasureTime frameDescription
Vein graft patency by CT angiography3-6 monthws
MACCE3-6 monthsMajor adverse cardiac and cerebral events

Countries

Germany, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026